Cart
sales@molnova.com
RS5517
CAS No. 2227017-46-9
RS5517( —— )
Catalog No. M37024 CAS No. 2227017-46-9
RS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 102 | Get Quote |
|
| 5MG | 150 | Get Quote |
|
| 10MG | 221 | Get Quote |
|
| 25MG | 361 | Get Quote |
|
| 50MG | 533 | Get Quote |
|
| 100MG | 761 | Get Quote |
|
| 500MG | 2358 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRS5517
-
NoteResearch use only, not for human use.
-
Brief DescriptionRS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.
-
DescriptionRS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2227017-46-9
-
Formula Weight390.86
-
Molecular FormulaC23H19ClN2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=CC=C(C=C1)CO)C=2NC=3C=CC(Cl)=CC3C2CC=4C=CC=CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Saponaro C, et al. β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. Oncogene. 2018 Jun;37(24):3301-3316. doi: 10.1038/s41388-018-0170-y. Epub 2018 Mar 19.
molnova catalog
related products
-
Cisd2 agonist 1
Cisd2 agonist 1 is a potent CDGSH iron-sulfur structural domain 2 (CISD2) agonist (EC50: 34 nM) with potential anticancer activity for the study of non-alcoholic fatty liver disease (NAFLD).
-
Sarmentine
SarMentine is a natural product for research related to life sciences.
-
Zedoarondiol
Zedoarondiol has anti-inflammatory activity, inhibits iNOS, COX-2, and pro-inflammatory cytokine expressions by suppressing the phosphorylations of IKK and MAPKs, and by subsequently inactivating the NF-kappaB pathway.
